Published in J Urol on June 01, 2007
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol (2014) 3.17
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int (2012) 2.37
The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol (2013) 2.10
Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance? J Urol (2015) 2.04
Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst (2010) 1.63
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer (2014) 1.55
Comparison of open and robotic-assisted prostatectomy: The University of British Columbia experience. Can Urol Assoc J (2014) 1.54
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J (2009) 1.51
What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology (2009) 1.49
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol (2015) 1.44
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42
Toward better use of bone scans among men with early-stage prostate cancer. Urology (2014) 1.41
Physician social networks and variation in prostate cancer treatment in three cities. Health Serv Res (2011) 1.40
Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer (2013) 1.31
Current use of PSMA-PET in prostate cancer management. Nat Rev Urol (2016) 1.27
Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer (2011) 1.26
Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy (2013) 1.25
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. Cancer (2011) 1.16
Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol (2010) 1.15
Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol (2009) 1.09
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol (2014) 1.09
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis (2012) 1.06
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract (2013) 1.05
Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? Adv Urol (2011) 1.05
Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer (2014) 1.04
Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics (2009) 1.03
Brachytherapy for prostate cancer: a systematic review. Adv Urol (2009) 1.02
Factors influencing patients' acceptance and adherence to active surveillance. J Natl Cancer Inst Monogr (2012) 1.00
Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res (2013) 0.99
Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J (2012) 0.99
Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med (2012) 0.98
Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. Prostate (2010) 0.97
Men's perspectives on selecting their prostate cancer treatment. J Natl Med Assoc (2011) 0.96
Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr Cancer (2010) 0.96
Radical prostatectomy for high-risk prostate cancer. World J Urol (2008) 0.96
Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study. PLoS Med (2016) 0.95
Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis (2015) 0.95
Upregulation of α-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways. Brain Behav Immun (2012) 0.94
Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. J Gen Intern Med (2015) 0.94
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. Eur Urol (2016) 0.93
RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Ann N Y Acad Sci (2010) 0.93
Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev (2013) 0.92
The example of CaPSURE: lessons learned from a national disease registry. World J Urol (2011) 0.92
Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int (2010) 0.92
Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol (2016) 0.91
Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy. Int J Clin Oncol (2014) 0.91
Mitochondria-related gene expression changes are associated with fatigue in patients with nonmetastatic prostate cancer receiving external beam radiation therapy. Cancer Nurs (2013) 0.91
Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer. Adv Urol (2012) 0.91
Is there an optimal management for localized prostate cancer? Clin Interv Aging (2010) 0.91
New Paradigms for Patient-Centered Outcomes Research in Electronic Medical Records: An Example of Detecting Urinary Incontinence Following Prostatectomy. EGEMS (Wash DC) (2016) 0.91
Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. BMJ Open (2014) 0.90
Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging (2016) 0.89
Brachytherapy in the therapy of prostate cancer - an interesting choice. Contemp Oncol (Pozn) (2013) 0.89
Predictive models for newly diagnosed prostate cancer patients. Rev Urol (2009) 0.89
Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy. World J Urol (2013) 0.89
Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol (2009) 0.89
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer. Cent European J Urol (2016) 0.88
Increasing use of observation among men at low risk for prostate cancer mortality. J Urol (2014) 0.88
What Is a "Good" Treatment Decision? Decisional Control, Knowledge, Treatment Decision Making, and Quality of Life in Men with Clinically Localized Prostate Cancer. Med Decis Making (2016) 0.88
Non-invasive molecular imaging of prostate cancer lymph node metastasis. Trends Mol Med (2009) 0.88
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
Imaging and evaluation of patients with high-risk prostate cancer. Nat Rev Urol (2015) 0.87
Statistical Shape Model for Manifold Regularization: Gleason grading of prostate histology. Comput Vis Image Underst (2013) 0.87
Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer. J Oncol Pract (2011) 0.87
Personality predicts prostate cancer treatment decision-making difficulty and satisfaction. Psychooncology (2009) 0.87
Focal therapy for prostate cancer: The current status. Prostate Int (2015) 0.86
The role of lymphadenectomy in high risk prostate cancer. World J Urol (2008) 0.86
Radiotherapy and survival in prostate cancer patients: a population-based study. Int J Radiat Oncol Biol Phys (2008) 0.86
3D vs 2D laparoscopic radical prostatectomy in organ-confined prostate cancer: comparison of operative data and pentafecta rates: a single cohort study. BMC Urol (2015) 0.85
The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions. Radiat Oncol (2014) 0.85
Patient and spouse illness beliefs and quality of life in prostate cancer patients. Psychol Health (2012) 0.85
Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer. Front Oncol (2015) 0.84
Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol (2013) 0.84
The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nat Rev Urol (2012) 0.84
Extended lymph node dissection in robot-assisted radical prostatectomy: lymph node yield and distribution of metastases. Asian J Androl (2014) 0.84
Regaining candidacy for heart transplantation after robotic assisted laparoscopic radical prostatectomy in left ventricular assist device patient. Case Rep Transplant (2012) 0.84
CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids (2015) 0.84
Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients. Onco Targets Ther (2013) 0.84
Current status of radical prostatectomy for high-risk prostate cancer. Korean J Urol (2014) 0.83
Screening for prostate cancer: a controversy or fact. Hippokratia (2010) 0.83
Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months. Support Care Cancer (2008) 0.83
Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. Am Health Drug Benefits (2013) 0.83
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool. World J Urol (2012) 0.83
Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters. Strahlenther Onkol (2009) 0.82
Functional and anatomical differences between continent and incontinent men post radical prostatectomy on urodynamics and 3T MRI: a pilot study. Neurourol Urodyn (2014) 0.82
Translational Molecular Imaging of Prostate Cancer. Curr Radiol Rep (2013) 0.82
Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. PLoS One (2013) 0.82
Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis (2014) 0.82
Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer (2010) 0.82
Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment. Antioxid Redox Signal (2014) 0.82
Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. Int J Radiat Oncol Biol Phys (2015) 0.81
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med (2010) 7.95
Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med (2007) 7.90
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
EAU guidelines on prostate cancer. Eur Urol (2007) 6.30
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol (2008) 4.90
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med (2012) 4.59
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2003) 4.28
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med (2006) 3.93
Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature (2002) 3.92
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
American Urological Association guideline on the management of priapism. J Urol (2003) 3.77
Prostate cancer. Lancet (2008) 3.69
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc (2012) 3.45
Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage (2002) 3.35
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol (2007) 3.26
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol (2011) 3.10
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol (2011) 3.00
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
Prevalence and risk factors for erectile dysfunction in the US. Am J Med (2007) 2.84
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc (2003) 2.75
Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof (2005) 2.69
What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol (2002) 2.64
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol (2013) 2.59
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol (2011) 2.51
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer (2014) 2.48
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Urodynamic measures do not predict stress continence outcomes after surgery for stress urinary incontinence in selected women. J Urol (2008) 2.43
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40